Namita Thapar-backed Emcure Pharma IPO opens for subscription. Should you bid?

Emcure Pharmaceuticals IPO, with marquee investors like Goldman Sachs, offers a fresh equity issuance and OFS. Namita Thapar to earn Rs 127 crore through the stake sale. The company targets debt repayment and global expansion.